Integrin 3D structures: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 53: | Line 53: | ||
**[[2vdm]], [[2vdn]], [[3t3m]], [[3t3p]] – hIG headpiece + antibody + antagonist + Mg<br /> | **[[2vdm]], [[2vdn]], [[3t3m]], [[3t3p]] – hIG headpiece + antibody + antagonist + Mg<br /> | ||
**[[2vdo]], [[2vdp]], [[2vdq]], [[2vdr]] – hIG headpiece + antibody + fibrinogen peptide + Mg<br /> | **[[2vdo]], [[2vdp]], [[2vdq]], [[2vdr]] – hIG headpiece + antibody + fibrinogen peptide + Mg<br /> | ||
**[[6v4p]] – hIG + antibody – Cryo-EM<br /> | **[[6v4p]], [[7la4]] – hIG + antibody – Cryo-EM<br /> | ||
**[[7l8p]], [[7tct]], [[7td8]], [[7tho]], [[7tmz]], [[7tpd]], [[7u60]], [[7u9f]], [[7u9v]], [[7ubr]], [[7ucy]], [[7udg]], [[7udh]], [[7ue0]], [[7ufh]], [[7uh8]], [[7uje]], [[7ujk]], [[7uk9]], [[7uko]], [[7ukp]], [[7ukt]] – hIG + antibody + drug<br /> | |||
*IG α-4 | *IG α-4 | ||
| Line 95: | Line 96: | ||
**[[1lfa]] - hIG I domain + Mn <br /> | **[[1lfa]] - hIG I domain + Mn <br /> | ||
**[[1zon]], [[4ixd]] - hIG I domain <br /> | **[[1zon]], [[4ixd]], [[7kc3]] - hIG I domain 153-334 <br /> | ||
**[[1mqa]] - hIG I domain (mutant) <br /> | **[[1mqa]] - hIG I domain (mutant) <br /> | ||
**[[1zoo]], [[1zop]], [[3f74]] - hIG I domain + Mg <br /> | **[[1zoo]], [[1zop]], [[3f74]] - hIG I domain + Mg <br /> | ||
**[[1mq9]] - hIG I domain (mutant) + Mn <br /> | **[[1mq9]] - hIG I domain (mutant) + Mn <br /> | ||
**[[1mjn]] - hIG I domain (mutant) + Mg <br /> | **[[1mjn]] - hIG I domain (mutant) + Mg <br /> | ||
**[[2k8o]] – hIG cytoplasmic domain (mutant) – NMR <br /> | |||
**[[5e6s]], [[5e6r]] – hIG AI, headpiece,pocket domains + Mg<br /> | **[[5e6s]], [[5e6r]] – hIG AI, headpiece,pocket domains + Mg<br /> | ||
**[[2m3e]] – hIG transmembrane domain - NMR<br /> | **[[2m3e]] – hIG transmembrane domain - NMR<br /> | ||
| Line 111: | Line 112: | ||
**[[1rd4]], [[2ica]], [[3bqm]], [[3bqn]], [[3e2m]] - hIG I domain + inhibitor<br /> | **[[1rd4]], [[2ica]], [[3bqm]], [[3bqn]], [[3e2m]] - hIG I domain + inhibitor<br /> | ||
**[[2o7n]], [[3m6f]] - hIG I domain + antagonist<br /> | **[[2o7n]], [[3m6f]] - hIG I domain + antagonist<br /> | ||
**[[1xdd]], [[1xdg]], [[1xuo]] - hIG I domain + inhibitor + Mg<br /> | **[[1xdd]], [[1xdg]], [[1xuo]], [[7kc5]] - hIG I domain + inhibitor + Mg<br /> | ||
**[[7kc6]] - hIG I domain + drug + Mg<br /> | |||
**[[3f78]] - hIG I domain + anesthetic + Mg<br /> | **[[3f78]] - hIG I domain + anesthetic + Mg<br /> | ||
**[[3eoa]], [[3eob]] - hIG I domain + antibody<br /> | **[[3eoa]], [[3eob]] - hIG I domain + antibody<br /> | ||
**[[3hi6]] - hIG I domain (mutant) + antibody + Mn<br /> | **[[3hi6]] - hIG I domain (mutant) + antibody + Mn<br /> | ||
*IG α-L + IG β-2 | |||
**[[5e6u]] – hIG headpiece (mutant) + Ni<br /> | |||
*IG α-M | *IG α-M | ||
| Line 126: | Line 132: | ||
**[[3q3g]], [[3qa3]] – hIG + antibody<br /> | **[[3q3g]], [[3qa3]] – hIG + antibody<br /> | ||
**[[4m76]] – hIG + complement C3<br /> | **[[4m76]] – hIG + complement C3<br /> | ||
**[[2lke]], [[2lkj – hIG cytoplasmic domain – NMR<br /> | **[[2lke]], [[2lkj]] – hIG cytoplasmic domain – NMR<br /> | ||
**[[4xw2]] – hIG + simvastatin<br /> | **[[4xw2]] – hIG + simvastatin<br /> | ||
**[[6rhv]], [[6rhw]] – hIG + cytolysin<br /> | **[[6rhv]], [[6rhw]] – hIG + cytolysin<br /> | ||
*IG α-M + IG β-2 | |||
**[[7usm]] – hIG ectodomain – Cryo EM<br /> | |||
**[[7usl]] – hIG ectodomain + adenylate cyclase toxin + antibody – Cryo EM<br /> | |||
**[[ | **[[7p2d]] – hIG ectodomain + nanobody <br /> | ||
**[[ | |||
**[[ | |||
*IG α-V + IG β-3 | *IG α-V + IG β-3 | ||
| Line 154: | Line 155: | ||
**[[6om2]] – hIG (mutant) + Protgf-b1 RGD peptide<br /> | **[[6om2]] – hIG (mutant) + Protgf-b1 RGD peptide<br /> | ||
**[[6uja]] – hIG + Protgf-b1 RGD – Cryo EM<br /> | **[[6uja]] – hIG + Protgf-b1 RGD – Cryo EM<br /> | ||
**[[7y1t]] – hIG + TGF-b1 – Cryo EM<br /> | |||
*IG α-X | *IG α-X | ||